Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection

Trial Profile

Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Fidaxomicin (Primary)
  • Indications Clostridium infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Oct 2017.
    • 22 Jun 2017 Planned initiation date changed from 1 Dec 2016 to 1 Jul 2017.
    • 15 Jun 2016 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top